Wouter Meuleman

Weve experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, Precede Bio developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

A network for entrepreneurs building in stealth. Submit your information here so investors can find you: harmonic.ai/get-discovered

DELFI uses AI, machine learning and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Bi Continental (US/European Union) Quantum AI Powered Stealth BioTech Startup

Fluent BioSciences, an Illumina company, is a biotechnology company with a mission to accelerate the understanding of biology and disease through simple, cost effective and scalable solutions for every laboratory from research to the clinic. Fluent’s breakthrough Pre-templated Instant Partitions (PIPseq™) technology enables near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. This powerful platform enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of discovery and disease applications including single-cell RNA sequencing (scRNA-Seq).

Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

Desktop Genetics is an international company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by the real-world impact of CRISPR technology. We have invested four years developing our core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers our flagship DESKGEN CRISPR Library product range, which enables the work of our pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics'​ tools and technologies are used by over 1800 organisations all over the world, and our projects contribute directly to several key partnerships to bring CRISPR into the clinic.

Biota is commercializing Biosurveillance for energy and industrial customers. We unlock the use of ever present microbes as sensors and tracers. Through our Biosurveillance Platform, Biota is able to extract this valuable data source, digitize it, and fill critical data gaps that other data sources are unable to provide. Our Biosurveillance Platform provides a non invasive, cost effective, 4D diagnostic that characterizes industrial environments and tracks the movement of both surface and subsurface fluids. Current and emerging applications cover energy, decarbonization, environmental monitoring, as well as industrial asset integrity.

Weve experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, Precede Bio developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.

RedShiftBio is redefining the possibilities for structural characterization of biomolecules. RedShiftBio has developed a proprietary life sciences platform combining our Microfluidic Modulation Spectroscopy (MMS) and expertise in high powered quantum cascade lasers that provides ultra-sensitive and ultra-precise measurements of molecular structure. These structural changes affect critical quality attributes governing the safety, efficacy, and stability of biomolecules and their raw materials. This combination of technologies is available to researchers in our fully-automated AQS³pro Analyzer and is backed by a global network of sales, applications, service, and support teams to address all market needs. Led by an experienced management team with a proven track record of success in both large instrumentation companies and commercializing disruptive technologies, RedShiftBio is here to support your research and development goals. Our instruments can be found in the majority of the leading biopharmaceutical companies in the world.

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. ​ We invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health. ​ Our strategic relationship with Illumina provides us access to the expertise and vision of the worlds leading genomics solutions provider. Our team members have decades of entrepreneurial experience in genomics and a passion for improving human health.

A network for entrepreneurs building in stealth. Submit your information here so investors can find you: harmonic.ai/get-discovered